Recognising and Managing DOAC Complications

Trending3.5(New)

Direct Oral Anticoagulants (DOACs) are increasingly prescribed for the prevention and treatment of thromboembolic disorders, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism. However, despite their convenience over traditional vitamin K antagonists (VKAs), DOACs present specific complications that healthcare professionals must recognize and manage to ensure patient safety. This course provides in-depth knowledge on how to identify and manage DOAC-related complications such as bleeding, thrombosis, and renal dysfunction. Participants will explore the pharmacology of DOACs, including the differences between available agents like rivaroxaban, apixaban, dabigatran, and edoxaban. The course covers common adverse effects and the mechanisms behind them, as well as strategies for managing overdose, bleeding, and drug interactions.

7 Modules1 hour
$169$0
Start Learning
Recognising and Managing DOAC Complications

Learning Outcomes

What you'll learn

  • Recognize the complications associated with DOAC therapy, including bleeding and thromboembolic events.
  • Understand the pharmacology of DOACs and the differences between agents such as rivaroxaban, apixaban, dabigatran, and edoxaban.
  • Effectively monitor and manage bleeding complications, including appropriate use of reversal agents.
  • Address renal dysfunction and drug interactions in patients taking DOACs.
  • Apply evidence-based strategies for managing DOAC overdose and patient-specific risks.
  • Educate patients on the potential risks and benefits of DOAC therapy, as well as the signs and symptoms of complications.

Stay updated with our

Healthcare trainingHealthcare training

Training Overview

  • Introduction to DOACs – Pharmacology and Mechanisms of Action
  • Identifying and Managing Bleeding Complications
  • Thrombosis in DOAC Therapy – Recognizing and Managing Clotting Events
  • Monitoring Renal Function in DOAC Therapy
  • Drug Interactions with DOACs
  • Patient Education and Adherence to DOAC Therapy
  • Summary
Healthcare trainingHealthcare trainingHealthcare trainingHealthcare trainingHealthcare trainingHealthcare trainingHealthcare training

Top reviews

No reviews yet.

You May Also Like

Take Your
Learning Anywhere

Stay on top of your learning with the Care Learning app.

Download on the App StoreGet it on Google Play

Are you a qualified
Trainer or Instructor?

Join Care Learning as a trainer and deliver high-quality courses to learners across healthcare and workplace training.

Refer a Friend &
Earn Rewards.

Invite healthcare professionals to join Care Learning and get rewarded when your referral successfully joins.

1 / 3

Frequently asked questions

The most common complications of DOAC therapy include bleeding, thrombosis, and drug interactions. Management includes dose adjustment, monitoring renal function, and using reversal agents when needed.

Bleeding in patients on DOACs can be managed by discontinuing the drug, administering reversal agents (such as andexanet alfa for Factor Xa inhibitors), and providing supportive measures like blood transfusions if necessary.

Renal function should be monitored regularly, especially in elderly patients or those with pre-existing kidney disease, as impaired renal function increases the risk of bleeding complications.

No, DOACs are contraindicated in patients with severe hepatic disease, especially those with hepatic impairment that leads to coagulopathy, as these patients may not be able to safely metabolize the drugs.

If a patient develops thrombosis despite being on DOAC therapy, therapy should be reassessed, possibly switching to other anticoagulants such as LMWH or warfarin.

Drug interactions can either increase the anticoagulant effect of DOACs (leading to bleeding) or reduce their effectiveness (leading to thrombosis).